

**IN THE CLAIMS:**

Please amend the claims as follows:

Claims 1-16 (**cancelled**).

Claim 17 (**original**): A pharmaceutical composition which comprises AZD2171, or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and a platinum anti-tumour agent, in association with a pharmaceutically acceptable excipient or carrier.

Claim 18 (**original**): A kit comprising AZD2171 or a pharmaceutically acceptable salt thereof, and a platinum anti-tumour agent.

Claim 19 (**currently amended**): A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need thereof such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of a platinum anti-tumour agent.

Claim 20 (**currently amended**): A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need thereof such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of a platinum anti-tumour agent and before, after or simultaneously with an effective amount of ionising radiation.

Claim 21 (**currently amended**): The A-method according to any one of claims 19, 20, 27, 28, 29 and 30 ~~claim 19 or claim 20~~ wherein AZD2171 is in a form of the free base.

Claim 22 (**currently amended**): The A-method according to any one of claims 19, 20, 27 and 28 ~~19-21~~ wherein the platinum anti-tumour agent is oxaliplatin.

Claim 23 (**currently amended**): The A-method according to any one of claims 19, 20, 27 and 28-19-21 wherein the platinum anti-tumour agent is cisplatin.

Claim 24 (**currently amended**): The A-method according to any one of claims 19, 20, 27 and 28-19-21 wherein the platinum anti-tumour agent is carboplatin.

Claim 25 (**currently amended**): A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded in need thereof animal such as a human, which comprises administering to said animal an effective amount of AZD2171 maleate salt before, after or simultaneously with an effective amount of oxaliplatin.

Claim 26 (**currently amended**): A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need thereof such as a human, which comprises administering to said animal an effective amount of AZD2171 maleate salt before, after or simultaneously with an effective amount of oxaliplatin and before, after or simultaneously with an effective amount of ionising radiation.

Claim 27 (**new**): A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of a platinum anti-tumour agent.

Claim 28 (**new**): A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of a platinum anti-tumour agent and before, after or simultaneously with an effective amount of ionising radiation.

Claim 29 (**new**): A method for the treatment of a cancer involving a solid tumour in a warm-blooded in need thereof, which comprises administering to said animal an effective

amount of AZD2171 maleate salt before, after or simultaneously with an effective amount of oxaliplatin.

**Claim 30 (new):** A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 maleate salt before, after or simultaneously with an effective amount of oxaliplatin and before, after or simultaneously with an effective amount of ionising radiation.